Manufacturers report positive results for reproxalap for ocular itching in allergic conjunctivitis

Results from the Phase III INVIGORATE trial show this small-molecule immune-modulating covalent inhibitor of RASP (reactive aldehyde species) significantly reduced ocular itching in patients with allergic conjunctivitis vs placebo.

Biospace Inc.